Compare Pfizer Inc (PFE) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Skyworks Solutions Inc — how do they compare? Pfizer Inc trades at $28.19 (market cap $158.56B), while Skyworks Solutions Inc trades at $77.13 (market cap $12.15B). The key difference: Pfizer Inc is far larger — about 13.1× Skyworks Solutions Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Skyworks Solutions Inc for 50 Days on average.
| PFE | SWKS | |
|---|---|---|
Market Cap | $158.56B | $12.15B |
Volume | 44,138,282 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $29.02 | $91.45 |
52-Week Low | $23.67 | $52.50 |
Typical Hold Time | 158 Days | 50 Days |
Enterprise Value | $210.06B | $12.03B |
Dividend Yield | 6.18% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Skyworks Solutions (SWKS) trades at $77.17, down 7.5% in the last session, with a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, but revenue and net income have declined year-over-year. The pending merger with Qorvo is a key development, with regulatory clearances obtained, targeting $500 million in synergies. Analyst consensus is a Buy with a $78.80 price target, slightly above the current price.
The outlook is mixed: the Qorvo merger offers growth potential and cost savings, but declining profitability and negative cash flow pose risks. Investor sentiment is cautious due to recent price volatility and earnings pressure. Upside depends on merger execution and market recovery, while downside risks include integration challenges and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
